Compare Amylx Pharmaceuticals Inc (AMLX) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Boston Beer Company Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while Boston Beer Company Inc trades at $177.42 (market cap $1.84B). The key difference: Amylx Pharmaceuticals Inc and Boston Beer Company Inc are close in size by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SAM | |
|---|---|---|
Market Cap | $1.98B | $1.84B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $260.05 |
52-Week Low | $7.64 | $161.08 |
Enterprise Value | $1.70B | $1.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SAM trades at $176.79, up 1.1% on the day, amid a bearish technical signal but with a consensus analyst price target of $222.67 suggesting upside. Recent earnings show volatility with a Q1 2026 miss, while full-year 2025 net income improved to $108.47M. Cash flow remains positive, but 2026 revenue and profit projections indicate challenges. The company is investing in brand innovation and Beyond Beer expansion to drive growth.
The outlook is mixed; valuation ratios appear reasonable, and strategic initiatives support long-term potential, but near-term volume pressure and negative 2026 profit forecasts pose risks. Investor sentiment is cautious, with most analysts rating Hold. Key catalysts include execution on cost savings and brand momentum against a competitive backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
